Bcl-2 gene silencing by RNA interference inhibits the growth of the human gallbladder carcinoma cell line GBC-SD in vitro and in vivo

Geng,Zhi-Min; Zhang,Min; Pan,Xiao-Tao; Wang,Lin

doi:10.3892/or.2013.2539

Bcl-2 gene silencing by RNA interference inhibits the growth of the human gallbladder carcinoma cell line GBC-SD in vitro and in vivo

Authors:
- Zhi-Min Geng
- Min Zhang
- Xiao-Tao Pan
- Lin Wang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, First Affiliated Hospital of the Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: June 12, 2013 https://doi.org/10.3892/or.2013.2539
Pages: 793-800

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gallbladder carcinoma is the most common malignant tumor in the biliary system; however, the underlying mechanisms of tumor initiation, progression and metastasis are not fully understood to date. The B-cell lymphoma/leukemia-2 (Bcl-2) gene, which is highly expressed in gallbladder carcinoma tissue, is one of the most important regulatory factors in cell apoptosis, and plays an important role in the initiation and progression of gallbladder carcinoma. In the present study, we constructed a eukaryotic expression vector of small interference RNA (siRNA) specific to the Bcl-2 gene and transfected it into GBC-SD human gallbladder carcinoma cells. We demonstrated that the constructed Bcl-2 siRNA vector effectively silenced Bcl-2 gene expression in the GBC-SD human gallbladder carcinoma cells, inhibited cell proliferation, induced cell apoptosis, increased chemotherapeutic sensitivity to 5-fluorouracil and inhibited tumor growth in vivo. Collectively, these data reveal an important contribution of Bcl-2 to gallbladder carcinoma. Thus, the use of a synthetic inhibitor of Bcl-2 may be a promising approach for the treatment of gallbladder carcinoma.

View Figures

View References

1	Lai CH and Lau WY: Gallbladder cancer - a comprehensive review. Surgeon. 6:101–110. 2008. View Article : Google Scholar
2	Zhu AX, Hong TS, Hezel AF and Kooby DA: Current management of gallbladder carcinoma. Oncologist. 15:168–181. 2010. View Article : Google Scholar : PubMed/NCBI
3	Miller J and Jarnagin WR: Gallbladder carcinoma. Eur J Surg Oncol. 34:306–312. 2008. View Article : Google Scholar
4	Pelengaris S, Khan M and Evan GI: Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:321–334. 2002. View Article : Google Scholar : PubMed/NCBI
5	Mikami T, Yanagisawa N, Baba H, Koike M and Okayasu I: Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer. 85:318–325. 1999. View Article : Google Scholar : PubMed/NCBI
6	Quan ZW, Wu K, Wang J, Shi W, Zhang Z and Merrell RC: Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 193:380–383. 2001. View Article : Google Scholar : PubMed/NCBI
7	Goldin RD and Roa JC: Gallbladder cancer: a morphological and molecular update. Histopathology. 55:218–229. 2009. View Article : Google Scholar : PubMed/NCBI
8	Shaffer EA: Gallbladder cancer: the basics. Gastroenterol Hepatol. 4:737–741. 2008.PubMed/NCBI
9	Weyhenmeyer B, Murphy AC, Prehn JH and Murphy BM: Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol. 34:192–199. 2012.PubMed/NCBI
10	García-Sáez AJ: The secrets of the Bcl-2 family. Cell Death Differ. 19:1733–1740. 2012.
11	Sasatomi E, Tokunaga O and Miyazaki K: Spontaneous apoptosis in gallbladder carcinoma. Relationships with clinicopathologic factors, expression of E-cadherin, bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer. 78:2101–2110. 1996. View Article : Google Scholar : PubMed/NCBI
12	Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature. 431:343–349. 2004. View Article : Google Scholar : PubMed/NCBI
13	Fjose A, Ellingsen S, Wargelius A and Seo HC: RNA interference: mechanisms and applications. Biotechnol Annu Rev. 7:31–57. 2001. View Article : Google Scholar
14	Maurya SK, Tewari M, Mishra RR and Shukla HS: Genetic aberrations in gallbladder cancer. Surg Oncol. 21:37–43. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kuroki T, Tajima Y, Matsuo K and Kanematsu T: Genetic alterations in gallbladder carcinoma. Surg Today. 35:101–105. 2005. View Article : Google Scholar
16	Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 226:1097–1099. 1984. View Article : Google Scholar : PubMed/NCBI
17	Mello CC and Conte D Jr: Revealing the world of RNA interference. Nature. 431:338–342. 2004. View Article : Google Scholar : PubMed/NCBI
18	Tyner J and Druker BJ: RNAi screen for therapeutic target in leukemia. Cell Cycle. 8:21442009. View Article : Google Scholar : PubMed/NCBI
19	Lima RT, Martins LM, Guimarães JE, Sambade C and Vasconcelos MH: Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 11:309–316. 2004. View Article : Google Scholar : PubMed/NCBI